Hikma Pharmaceuticals (LON:HIK) Rating Reiterated by Barclays

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “equal weight” rating restated by equities research analysts at Barclays in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a GBX 2,000 ($25.31) price target on the stock. Barclays‘s price target would indicate a potential upside of 10.07% from the company’s current price.

Separately, Berenberg Bank increased their price objective on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.81) to GBX 2,000 ($25.31) and gave the company a “hold” rating in a report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 2,068.75 ($26.18).

Hikma Pharmaceuticals Price Performance

HIK opened at GBX 1,817 ($23.00) on Monday. The company’s 50 day simple moving average is GBX 1,920.43 and its 200-day simple moving average is GBX 1,890.69. Hikma Pharmaceuticals has a one year low of GBX 1,711 ($21.66) and a one year high of GBX 2,222 ($28.12). The stock has a market capitalization of £4.03 billion, a P/E ratio of 2,711.94, a price-to-earnings-growth ratio of 2.38 and a beta of 0.45. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded.